About Murli Krishna Pharma
Murli Krishna Pharma is a company based in Pune (India) founded in 2004 by Vijay K. Shastri and Satya Vadlamani. Murli Krishna Pharma has raised $11.19 million across 6 funding rounds from investors including InvAscent, Bowland Investment and Murli Krishna Exports. The company has 218 employees. Murli Krishna Pharma offers products and services including Tablets, Capsules, Injectables, and Oral Liquids.
- Headquarter Pune, India
- Employees 218
- Founders Vijay K. Shastri, Satya Vadlamani
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website murlikrishnapharma.com
- Social LinkedIn X Facebook Instagram YouTube
- Legal Name Murli Krishna Pharma Private Limited
- Date of Incorporation 02 Apr, 2004
- Jurisdiction Pune, Maharashtra, India
- Annual Revenue₹147 Cr
FY 2025 · -21% YoY
- Net Profit₹1.74 Cr
FY 2025 · 1% margin
- EBITDA₹10.33 Cr
FY 2025 · 7% margin
- Total Equity Funding$11.19M (USD)
in 6 rounds
- Latest Funding Round$9.26M (USD), Series A
May 2020
- InvestorsInvAscent
& 13 more
- Employee Count218
Associated legal entities of Murli Krishna Pharma
Murli Krishna Pharma operates through Murli Krishna Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Murli Krishna Pharma Private Limited CIN U24230PN2004PTC206917 | Active | 02 Apr 2004 | Pune, Maharashtra | ₹147 Cr | 218 | 4 | View details |
Products & Services of Murli Krishna Pharma
Murli Krishna Pharma offers a comprehensive portfolio of products and services, including Tablets, Capsules, Injectables, and Oral Liquids.
Formulations for accurate dosing and drug distribution
Encapsulation for customized drug delivery
Solutions for therapeutic administration
Formulations for patient bioavailability
Apps and channels of Murli Krishna Pharma
its YouTube channel Murli Krishna Pharma has 61 subscribers and 4 videos.
Videos from Murli Krishna Pharma
The most watched videos on Murli Krishna Pharma's YouTube channel, Murli Krishna Pharma (61 subscribers). Click a video to play it here.
More on Murli Krishna Pharma.
Funding Insights of Murli Krishna Pharma
Murli Krishna Pharma has successfully raised a total of $11.19M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $9.26 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.19M
- Total Rounds 6
- Last Round Series A — $9.26M
- First Round $111,181
(Dec 2007)
- Investors Count 14
All 6 funding rounds of Murli Krishna Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $9.26M | Series A | – | InvAscent | – |
| Aug 2014 | $245,106 | Seed | $4.15M | Bowland Investment | |
| Apr 2013 | $223,061 | Seed | $4.47M | Bowland Investment | |
| Nov 2010 | $1.11M | Seed | $••••• | Umoja | – |
| Sep 2009 | $239,143 | Seed | $••••• | Kryton | |
| Dec 2007 | $111,181 | Seed | $••••• | VM Mohan, Murli Krishna Exports |
| Date | Valuation | Stage |
|---|---|---|
| Aug 2014 | $4.15M | •••••••• |
| Apr 2013 | $4.47M | •••••••• |
| Nov 2010 | $••••• | •••••••• |
| Sep 2009 | $••••• | •••••••• |
Full valuation and stage history of Murli Krishna Pharma
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $4.15M (Aug 2014). 14 investors in total: 7 institutional and 7 angel.
Investors in Murli Krishna Pharma
Murli Krishna Pharma has secured backing from 14 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include InvAscent, Bowland Investment and Murli Krishna Exports.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on life sciences investments in India. | 2005 | invascent.com | - | |
- | – | bowlandinvestment.tcc.mode | - | |
Manufactures and exports pharmaceutical, veterinary, cosmetics, and animal feed ingredients to international markets. | 1999 | mkepl.com | Mumbai, India | |
- | – | hamzainvestment.tcc.mode | - | |
- | – | umoja.tcc.mode | - | |
Offers concrete waterproofing admixtures and repair solutions for buildings and infrastructure. | 1973 | kryton.com | Vancouver, Canada | |
- | – | murlikrishnaexports.tcc.mode | - | |
CS CR Sharma | - | – | unknown_42ca9cca11734dab9 | - |
BR Bhaskara Ramamurti | - | – | unknown_fc428f16bac34ad8a | - |
RS Ravi Srinivas | - | – | unknown_6da679c8a73f4e378 | - |
Investor details for Murli Krishna Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Murli Krishna Pharma Private Limited (Murli Krishna Pharma)
Murli Krishna Pharma Private Limited is the primary company behind Murli Krishna Pharma. The board of Murli Krishna Pharma Private Limited currently have 4 directors; the longest-serving is Satya Ramani Vadlamani, appointed in 2004. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Satya Ramani Vadlamani DIN 00009269 | Managing Director | 02 Apr 2004 | 22 yrs 6 mo | Murli Krishna Pharma Private Limited |
| Vijay Shastri Kalyanasundaram DIN 00009150 | Director | 02 Apr 2004 | 22 yrs 6 mo | Murli Krishna Pharma Private Limited |
| Nithyagovind DIN 08180238 | Nominee Director | 27 May 2020 | 6 yrs 4 mo | Murli Krishna Pharma Private Limited |
| Venkat Murli Krishna Vadlamani DIN 10705395 | Director | 15 Jul 2024 | 2 yrs 2 mo | Murli Krishna Pharma Private Limited |
People of Murli Krishna Pharma
2 people are tracked at Murli Krishna Pharma (2 in leadership); the tracked headcount is 218.
| Name | Role | Group |
|---|---|---|
| Co-Founder & Director | Leadership | |
| Co-Founder & Chairman | Leadership |
Complete people profiles for Murli Krishna Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Murli Krishna Pharma
Figures of Murli Krishna Pharma Private Limited, the primary company behind Murli Krishna Pharma, for FY 2025. Revenue was ₹147 Cr (-21% year on year). Net profit was ₹1.74 Cr (1% margin). EBITDA was ₹10.33 Cr (7% margin). Revenue has grown at a compounded annual rate of +11% over three years and +15% over five years.
- ₹147 CrRevenue · FY 2025 · -21% YoY
- ₹1.74 CrNet profit · 1% margin
- ₹10.33 CrEBITDA · 7% margin
- ₹5.39 CrPaid-up capital
- 218Employees (provident fund records)
- +11%Revenue CAGR, 3 years
- +15%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Murli Krishna Pharma Private Limited are on its company page.
Detailed financial statements for Murli Krishna Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Murli Krishna Pharma
4 dated milestones of Murli Krishna Pharma across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Murli Krishna Pharma is founded.
- Funding First funding round of $111K.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series A, of $9.3M.
Web traffic of Murli Krishna Pharma
The website of Murli Krishna Pharma (murlikrishnapharma.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 49.4% vs previous month
Websites whose visitors overlap most with Murli Krishna Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
hitachi.asia | hitachi.asia | 100% | – | #1,259,072 | – |
Latest news on Murli Krishna Pharma
Complete news archive for Murli Krishna Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Murli Krishna Pharma
10 companies that operate in the same segment as Murli Krishna Pharma (Traditional Health & Nutrition), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | – | USD 3.02 B | 8,300 | |
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | – | USD 5.1 B | 13,500 | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | Petah Tikva, Central District, Israel | USD 500 M | USD 18.74 B | 51,792 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | – | USD 508.93 M | 5,180 | |
Pharmaceutical products are developed and marketed globally. | 2009 | Montville, New Jersey, United States | USD 155.92 M | – | – | |
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | – | USD 6.21 B | 25,870 | |
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations | 1991 | Delhi, Delhi, India | USD 367.2 M | USD 1.52 B | 21,320 | |
Generics, biosimilars, APIs, and vaccines are manufactured by Wockhardt. | 1967 | Mumbai, Maharashtra, India | – | USD 353.53 M | 3,410 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Murli Krishna Pharma
Murli Krishna Pharma was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Murli Krishna Pharma is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Murli Krishna Pharma is a funded company, having raised a total of $11.19M across 6 funding rounds to date. The company's 1st funding round was a Seed of $111.18K, raised on Dec 2007.
Murli Krishna Pharma has 218 employees.
The primary company behind Murli Krishna Pharma, Murli Krishna Pharma Private Limited, reported revenue of ₹147 Cr for FY 2025, down 21% year on year.
Murli Krishna Pharma was established in 2004 and is based in Pune, India. Operations are centered in the pharmaceutical sector, with a focus on manufacturing intermediate drugs for formulations. The company is led by co-founders Vijay K. Shastri, serving as Director, and Satya Vadlamani, acting as Chairman. Production activities support drug development processes in the region.
Murli Krishna Pharma offers Tablets, Capsules, Injectables, and Oral Liquids.
Murli Krishna Pharma has 14 investors. Key investors include InvAscent, Bowland Investment, Murli Krishna Exports, Hamza Investment, and Umoja.
The valuation of Murli Krishna Pharma is $4.15M as of Aug 2014.
Murli Krishna Pharma operates through Murli Krishna Pharma Private Limited.
The legal entities of Murli Krishna Pharma currently have 4 directors, including Nithyagovind, Satya Ramani Vadlamani, Venkat Murli Krishna Vadlamani and others.